The XRP Ledger Operations team released an update, xrpld version 3.4.1, on September 25, 2026. This technical update addresses a batch-related issue in the software. Importantly, the update did not cause any disruptions to the XRP Ledger mainnet, ensuring asset integrity and stable operations. This maintenance reflects ongoing efforts to improve the ledger's reliability and performance.
The XRP Ledger Operations team update is the subject, with Pluang market data providing context. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 02, 2026 03:52 WIB: 32 of 50 major cryptocurrencies rose and 17 fell. Polkadot (DOT) traded at Rp21.329 with 31% sell and 69% buy orders. Litecoin (LTC) was priced at Rp1.228.546 with 47% sell and 53% buy activity. Tezos (XTZ) stood at Rp5.819 with similar order activity ratios.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
